Intercell AG

--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------

06.12.2006

» Vienna-based Pelias AG focuses on the development of novel vaccines
against      hospital-acquired infections - the company’s lead product,
a novel protein      based vaccine against Pseudomonas infections, is
in clinical trials » Full integration of vaccine projects in the
field of hospital-acquired      infections will strengthen Intercell’s
product portfolio and strategic focus      in a market with high unmet
medical need » As consideration for the acquired shares, up to
350,000 new Intercell shares      from existing authorized capital will
be offered to selling Pelias      shareholders

Intercell AG today announced its intention to increase its shareholding in the Vienna-based Pelias Biomedical Development AG ("Pelias") from currently 46 percent to a shareholding of 100 percent. In an all-share deal, Intercell offers up to 350,000 new Intercell shares, representing about 0.9 percent of Intercell’s current share capital, to the remaining private shareholders of Pelias. The transaction, which is subject to certain closing conditions required by Austrian law, is expected to close early 2007.

Pelias develops products and holds certain licenses in the field of vaccines against important pathogens involved in hospital-acquired infections, including a clinical stage Pseudomonas vaccine candidate and a number of antigens, which have been identified by Intercell’s proprietary Antigen Identification Program (AIP®). Hospital-acquired infections are one of the major causes of death and serious illness worldwide and result in an annual burden of USD 20 billion in the developed world.

"The attractive product portfolio combined with our enabling technologies offer us a unique opportunity to expand our globally leading position as technology provider and vaccine developer in the field of hospital-acquired infections", states Intercell's CEO Gerd Zettlmeissl.

"Our clinical progress with our Japanese Encephalitis vaccine and our strong financial position allow us to broaden our pipeline in an attractive field with high unmet medical need. Our enlarged product portfolio will support our position in leading vaccine innovation without any major implications on our business plan", states Werner Lanthaler, CFO of Intercell.

About hospital-acquired infections

Nosocomial infections - or hospital acquired infections - are bacterial or fungal infections which are acquired in a hospital setting and cause a variety of severe infections, many life-threatening such as pneumonia, sepsis and bacteremia.  Each year, around 2 million infections and 100,000 deaths occur in the US alone due to nosocomial infections. The annual burden to the society is constantly increasing due to the antibiotics resistance of the most problematic bacteria. In the field of S. aureus infections Intercell has a strong strategic alliance with Merck & Co., Inc. with a vaccine product in clinical trials.

Market Potential

Hospital-acquired infections represent a large market with an urgent, unmet medical need:

» Nosocomial infections are one of the major causes of death and
serious      illness worldwide. » Conservative estimates put the number
of hospital-acquired infections at      around 2 million per year only
in the US, leading to around 100,000 deaths      and resulting into an
accumulated annual burden of more than USD 20 billion      in the
developed world. » These numbers are expected to more than double by
2010. The combined market      volume in the US and EU is currently
estimated at around USD 5 billion.

end of announcement                                                 euro adhoc 06.12.2006 07:03:02
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market